Knockdown of TBK1 with its siRNA enhanced the antitumor activation of molecular-targeted drugs on HCC cells, and the drugs’ IC50 values decreased (Tables 5 and Table 6). The gene discussed is TBK1; the disease is hepatocellular carcinoma.